Prenatal exposure to solar radiation and hypertensive disorders of pregnancy.

OBJECTIVE: To examine the association between prenatal exposure to solar radiation and hypertensive disorders of pregnancy (HDP). DESIGN: A multicentre retrospective study. SETTING: 19 hospitals in the USA. POPULATION: 205 888 women with singleton gestation from the Consortium on Safe Labor (2002-2008). MAIN OUTCOME MEASURES: Gestational hypertension, pre-eclampsia/eclampsia, and pre-eclampsia superimposed on chronic hypertension. METHODS: Medical records of the participants were linked to solar radiation obtained from the National Solar Radiation Database. Average daily solar radiation of each woman was estimated over the entire pregnancy period and over three trimesters during pregnancy according to hospital sites. Generalised estimated equation was applied to investigate the relationship between quartiles of average daily solar radiation and HDP. Restricted cubic spline was applied to assess the nonlinear associations. RESULTS: Higher average solar radiation during the entire pregnancy was associated with reduced risks of HDP. Compared with the 1st quartile of solar radiation during the entire pregnancy, odds ratios (ORs) of the 2nd, 3rd and 4th quartiles were respectively 0.80 (95% CI 0.72-0.90), 0.63 (95% CI 0.55-0.73), 0.65 (95% CI 0.54-0.78) for gestational hypertension; 0.66 (95% CI 0.57-0.76), 0.61 (95% CI 0.51-0.73), 0.77 (95% CI 0.62-0.95) for pre-eclampsia, and 0.44 (95% CI 0.36-0.55), 0.42 (95% CI 0.35-0.49), 0.60 (95% CI 0.46-0.78) for superimposed pre-eclampsia. CONCLUSION: Exposure to higher daily solar radiation during pregnancy is associated with a decreased risk of HDP. The protective effect was stronger for superimposed pre-eclampsia than for pre-eclampsia or gestational hypertension. TWEETABLE ABSTRACT: Exposure to higher daily solar radiation during pregnancy is associated with a decreased risk of HDP.

Neonatal outcomes following exposure in utero to fallout from Chernobyl.

Iodine 131 (I-131), the principal component of nuclear fallout from the Chernobyl accident, concentrates in the thyroid gland and may pose risks to fetal development. To evaluate this, neonatal outcomes following the accident in April of 1986 were investigated in a cohort of 2582 in utero-exposed individuals from northern Ukraine for whom estimates of fetal thyroid I-131 dose were available. We carried out a retrospective review of cohort members' prenatal, delivery and newborn records. The relationships of dose with neonatal anthropometrics and gestational length were modeled via linear regression with adjustment for potentially confounding variables. We found similar, statistically significant dose-dependent reductions in both head circumference (-1.0 cm/Gy, P = 0.005) and chest circumference (-0.9 cm/Gy, P = 0.023), as well as a similar but non-significant reduction in neonatal length (-0.6 cm/Gy, P = 0.169). Gestational length was significantly increased with increasing fetal dose (0.5 wks/Gy, P = 0.007). There was no significant (P > 0.1) effect of fetal dose on birth weight. The observed associations of radioiodine exposure with decreased head and chest circumference are consistent with those observed in the Japanese in utero-exposed atomic bomb survivors.

In utero exposure to iodine-131 from Chernobyl fallout and anthropometric characteristics in adolescence.

Prenatal exposure to external radiation has been linked to growth retardation among atomic bomb survivors in adolescence. It is unclear from previous studies whether in utero exposure to internal radiation such as iodine-131 (I-131), which concentrates in the thyroid gland, has an effect on physical growth. We examined the associations between estimated thyroid gland dose from prenatal exposure to I-131 and self-reported height and weight in a cohort of 2,460 individuals exposed to radioactive fallout from the 1986 Chernobyl nuclear accident [mean I-131 dose = 72 (mGy)] and screened for thyroid diseases in adolescence. Using multivariable linear regression models, we estimated the mean differences in height, weight and body mass index (BMI) per unit increase in dose (100 mGy) in models adjusted for gender, age at examination, type of residence (rural/urban) and presence of thyroid disease diagnosed at screening. All of the adjustment factors as well as the trimester of exposure were evaluated as potential modifiers of the dose response. Overall, no significant dose response was found for height (P = 0.29), weight (P = 0.14) or BMI (P = 0.16). We found significant modification of the dose response for weight and BMI by presence/absence of thyroid disease (P = 0.02 and P = 0.03, respectively), but not for other factors. In individuals without thyroid disease (n = 1,856), there was a weak, significant association between I-131 thyroid dose and higher weight (210 g per 100 mGy, P = 0.02) or BMI (70 g/m² per 100 mGy, P = 0.02) that depended on individuals (n = 52) exposed to ≥500 mGy. In individuals with thyroid disease (n = 579, 67.4% with simple diffuse goiter) no significant association with I-131 for weight (P = 0.14) or BMI (P = 0.14) was found. These results do not support the hypothesis that in utero exposure to I-131 at levels experienced by a majority of study subjects may be associated with meaningful differences in adolescent anthropometry. However, additional studies are needed to clarify whether in utero exposure to I-131 at levels > = 500 mGy may be associated with increases in weight/BMI and to evaluate the confounding or modifying role of thyroid disease, past iodine deficiency, maternal and prenatal/postnatal factors.

A method of estimating conceptus doses resulting from multidetector CT examinations during all stages of gestation.

PURPOSE: Current methods for the estimation of conceptus dose from multidetector CT (MDCT) examinations performed on the mother provide dose data for typical protocols with a fixed scan length. However, modified low-dose imaging protocols are frequently used during pregnancy. The purpose of the current study was to develop a method for the estimation of conceptus dose from any MDCT examination of the trunk performed during all stages of gestation. METHODS: The Monte Carlo N-Particle (MCNP) radiation transport code was employed in this study to model the Siemens Sensation 16 and Sensation 64 MDCT scanners. Four mathematical phantoms were used, simulating women at 0, 3, 6, and 9 months of gestation. The contribution to the conceptus dose from single simulated scans was obtained at various positions across the phantoms. To investigate the effect of maternal body size and conceptus depth on conceptus dose, phantoms of different sizes were produced by adding layers of adipose tissue around the trunk of the mathematical phantoms. To verify MCNP results, conceptus dose measurements were carried out by means of three physical anthropomorphic phantoms, simulating pregnancy at 0, 3, and 6 months of gestation and thermoluminescence dosimetry (TLD) crystals. RESULTS: The results consist of Monte Carlo-generated normalized conceptus dose coefficients for single scans across the four mathematical phantoms. These coefficients were defined as the conceptus dose contribution from a single scan divided by the CTDI free-in-air measured with identical scanning parameters. Data have been produced to take into account the effect of maternal body size and conceptus position variations on conceptus dose. Conceptus doses measured with TLD crystals showed a difference of up to 19% compared to those estimated by mathematical simulations. CONCLUSIONS: Estimation of conceptus doses from MDCT examinations of the trunk performed on pregnant patients during all stages of gestation can be made using the method developed in the current study.